H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Genmab (GMAB) to $37 from $50 and keeps a Buy rating on the shares following the Q4 report.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab’s Strong Financial Performance and Strategic Positioning Justify Buy Rating Despite Minor Setbacks
- Genmab A/S Advances Share Buy-back Program as of April 2025
- Genmab Discloses Managerial Share Transactions
- Genmab downgraded to Underperform from Market Perform at Bernstein
- Genmab A/S Faces Sell Rating Amid Hexabody Setbacks and Darzalex Patent Concerns
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue